Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022.
The announcement highlights:
- MagSense® HER2 breast cancer study interim results released during the quarter
- Move to new R&D facility completed
- Sponsored Research Agreement executed with researchers at Massachusetts
Read the full announcements here: Quarterly Activity Report and Appendix 4C